Review and update in the diagnosis of peripheral nerve sheath tumors.
Journal
Current opinion in neurology
ISSN: 1473-6551
Titre abrégé: Curr Opin Neurol
Pays: England
ID NLM: 9319162
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
25
8
2020
medline:
8
5
2021
entrez:
25
8
2020
Statut:
ppublish
Résumé
Although tumors with nerve sheath differentiation are vast, the main clinically significant problems faced by the pathologist are the separation of malignant peripheral nerve sheath tumors (MPNSTs) from histologic mimics, the diagnosis of neurofibromatous neoplasms with atypical features, and the separation of cutaneous neurofibromatous neoplasms from melanoma. This review briefly discusses a variety of common nerve sheath tumors and summarizes recent advances on these diagnostic fronts. Much of recent work has focused on abnormalities in polycomb repressive complex 2, and the ways in which these abnormalities may be exploited in the diagnosis of MPNSTs. Progress has been made in the diagnostic and clinical understanding of atypical neurofibromatous neoplasms and low-grade MPNSTs. A number of reports have explored the diagnostic distinction between cutaneous neurofibroma and melanoma. New discoveries show promise in the diagnosis of peripheral nerve sheath tumors, but challenges - old and new - remain.
Identifiants
pubmed: 32833749
doi: 10.1097/WCO.0000000000000857
pii: 00019052-202010000-00007
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
575-586Références
Magro G, Amico P, Vecchio GM, et al. Multinucleated floret-like giant cells in sporadic and NF1-associated neurofibromas: a clinicopathologic study of 94 cases. Virchows Arch 2010; 456:7176.
Elsensohn A, Shiu J, Grove N, et al. Distinguishing neurofibroma from desmoplastic melanoma: the value of p53. Am J Surg Pathol 2018; 42:372375.
Yeh I, McCalmont TH. Distinguishing neurofibroma from desmoplastic melanoma: the value of the CD34 fingerprint. J Cutan Pathol 2011; 38:625630.
Chen Y, Klonowski PW, Lind AC, Lu D. Differentiating neurotized melanocytic nevi from neurofibromas using melan-A (MART-1) immunohistochemical stain. Arch Pathol Lab Med 2012; 136:810815.
Husain S, Silvers DN. Fingerprint CD34 immunopositivity to distinguish neurofibroma from an early/paucicellular desmoplastic melanoma can be misleading. J Cutan Pathol 2013; 40:985987.
Fetsch JF, Michal M, Miettinen M. Pigmented (melanotic) neurofibroma: a clinicopathologic and immunohistochemical analysis of 19 lesions from 17 patients. Am J Surg Pathol 2000; 24:331343.
Schaffer JV, Chang MW, Kovich OI, et al. Pigmented plexiform neurofibroma: distinction from a large congenital melanocytic nevus. J Am Acad Dermatol 2007; 56:862868.
Pižem J, Nicholson KM, Mraz J, Prieto VG. Melanocytic differentiation is present in a significant proportion of nonpigmented diffuse neurofibromas: a potential diagnostic pitfall. Am J Surg Pathol 2013; 37:11821191.
Ball NJ, Kho GT. Melanocytic nevi are associated with neurofibromas in neurofibromatosis, type I, but not sporadic neurofibromas: a study of 226 cases. J Cutan Pathol 2005; 32:523532.
Gutzmer R, Herbst R, Mommert S, et al. Allelic loss at the neurofibromatosis type 1 (NF1) gene locus is frequent in desmoplastic neurotropic melanoma. Hum Genet 2000; 107:357361.
Wiesner T, Kiuru M, Scott SN, et al. NF1 mutations are common in desmoplastic melanoma. Am J Surg Pathol 2015; 39:13571362.
Machado I, Llombart B, Cruz J, et al. Desmoplastic melanoma may mimic a cutaneous peripheral nerve sheath tumor: report of 3 challenging cases. J Cutan Pathol 2017; 44:632638.
Cirenajwis H, Lauss M, Ekedahl H, et al. NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics. Mol Oncol 2017; 11:438451.
Jour G, Andeen NK, Al-Rohil R, et al. Novel enriched pathways in superficial malignant peripheral nerve sheath tumours and spindle/desmoplastic melanomas. J Pathol 2018; 244:97106.
Jour G, Vasudevaraja V, Prieto VG, et al. BCAT1 and miR-2504: novel methylome signature distinguishes spindle/desmoplastic melanoma from superficial malignant peripheral nerve sheath tumor. Mod Pathol 2019; 32:338345.
Ntala C, Biswas A. Spectrum of melanocytic proliferation/differentiation in a large series of cutaneous neurofibromas: an under-recognized histopathologic phenomenon and potential clue for neurofibromatosis type 1. Am J Dermatopathol 2020; 42:165172.
Azizi AA, Slavc I, Theisen BE, et al. Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [18 F]FDG-PET imaging: is it of value in asymptomatic patients? Pediatr Blood Cancer 2018; 65:e26733.
Brinkman M, Jentjens S, Boone K, et al. Evaluation of the most commonly used (semi-)quantitative parameters of 18F-FDG PET/CT to detect malignant transformation of neurofibromas in neurofibromatosis type 1. Nucl Med Commun 2018; 39:961968.
Miettinen MM, Antonescu CR, Fletcher CD, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1: a consensus overview. Hum Pathol 2017; 67:110.
Beert E, Brems H, Daniëls B, et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Electron J Res Educ Psychol 2004; 2:134.
Bernthal NM, Putnam A, Jones KB, et al. The effect of surgical margins on outcomes for low grade MPNSTs and atypical neurofibroma. J Surg Oncol 2014; 110:813816.
Okada K, Hasegawa T, Tajino T, et al. Clinical relevance of pathological grades of malignant peripheral nerve sheath tumor: a multiinstitution TMTS study of 56 cases in northern Japan. Ann Surg Oncol 2007; 14:597604.
Valentin T, Le Cesne A, Ray-Coquard I, et al. Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer 2016; 56:7784.
Carrió M, Gel B, Terribas E, et al. Analysis of intratumor heterogeneity in neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: correlating histological and genomic findings. Hum Mutat 2018; 39:11121125.
Amirnasr A, Verdijk RM, Van Kuijk PF, et al. Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors. Sci Rep 2020; 10:114.
Higham CS, Dombi E, Rogiers A, et al. The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. Neuro Oncol 2018; 20:818825.
Nelson CN, Dombi E, Rosenblum JS, et al. Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1. J Neurosurg 2019; 1 ((aop)):111.
Hornick JL, Fletcher CD. Soft tissue perineurioma: clinicopathologic analysis of 81 cases including those with atypical histologic features. Am J Surg Pathol 2005; 29:845858.
Fanburg-Smith JC, Meis-Kindblom JM, Fante R, Kindblom LG. Malignant granular cell tumor of soft tissue: diagnostic criteria and clinicopathologic correlation. Am J Surg Pathol 1998; 22:779794.
Pareja F, Brandes AH, Basili T, et al. Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. Nat Commun 2018; 9:3533.
Sekimizu M, Yoshida A, Mitani S, et al. Frequent mutations of genes encoding vacuolar H+-ATPase components in granular cell tumors. Genes Chromosom Cancer 2019; 58:373380.
Perret RE, Jullie ML, Vergier B, et al. A subset of so-called dermal nonneural granular cell tumours are underlined by ALK fusions, further supporting the idea that they represent a variant of epithelioid fibrous histiocytoma. Histopathology 2018; 73:532534.
Cohen JN, Yeh I, Jordan RC, et al. Cutaneous non-neural granular cell tumors harbor. Am J Surg Pathol 2018; 42:11331142.
Imanishi J, Yazawa Y, Saito T, et al. Atypical and malignant granular cell tumors in Japan: a Japanese Musculoskeletal Oncology Group (JMOG) study. Int J Clin Oncol 2016; 21:808816.
Jo VY, Fletcher CD. SMARCB1/INI1 loss in epithelioid schwannoma. Am J Surg Pathol 2017; 41:10131022.
Torres-Mora J, Dry S, Li X, et al. Malignant melanotic schwannian tumor. Am J Surg Pathol 2014; 38:94105.
WHO Classification of Tumors Editorial Board. Soft tissue and bone tumors. International Agency for Research on Cancer, 5th edLyon, France: 2020.
Lindholm K, Moran CA. Primary mediastinal melanotic schwannian tumors: a clinicopathological and immunohistochemical study of 5 cases. Ann Diagn Pathol 2018; 37:103106.
Jo VY, Fletcher CD. Epithelioid malignant peripheral nerve sheath tumor: clinicopathologic analysis of 63 cases. Am J Surg Pathol 2015; 39:673682.
Allison KH, Patel RM, Goldblum JR, Rubin BP. Superficial malignant peripheral nerve sheath tumor: a rare and challenging diagnosis. Am J Clin Pathol 2005; 124:685692.
Lee W, Teckie S, Wiesner T, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 2014; 46:12271232.
Kirmizis A, Bartley SM, Kuzmichev A, et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev 2004; 18:15921605.
Prieto-Granada CN, Wiesner T, Messina JL, et al. Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST. Am J Surg Pathol 2016; 40:479489.
Cleven AH, Sannaa GA, Briaire-de Bruijn I, et al. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol 2016; 29:582590.
Schaefer IM, Fletcher CD, Hornick JL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol 2016; 29:413.
Le Guellec S, Macagno N, Velasco V, et al. Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. Mod Pathol 2017; 30:16771687.
Busam KJ, Shah KN, Gerami P, et al. Reduced H3K27me3 expression is common in nodular melanomas of childhood associated with congenital melanocytic nevi but not in proliferative nodules. Am J Surg Pathol 2017; 41:396404.
Asano N, Yoshida A, Ichikawa H, et al. Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumours. Histopathology 2017; 70:385393.
Marchione DM, Lisby A, Viaene AN, et al. Histone H3K27 dimethyl loss is highly specific for malignant peripheral nerve sheath tumor and distinguishes true PRC2 loss from isolated H3K27 trimethyl loss. Mod Pathol 2019; 32:14341446.
Makise N, Sekimizu M, Kubo T, et al. Clarifying the distinction between malignant peripheral nerve sheath tumor and dedifferentiated liposarcoma. Am J Surg Pathol 2018; 42:656664.
Makise N, Sekimizu M, Konishi E, et al. H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features. Mod Pathol 2019; 32:435445.
Hornick JL, Nielsen GP. Beyond ‘Triton’ malignant peripheral nerve sheath tumors with complete heterologous rhabdomyoblastic differentiation mimicking spindle cell rhabdomyosarcoma. Am J Surg Pathol 2019; 43:13231330.
Meyer A, Billings SD. What's new in nerve sheath tumors. Virchows Arch 2019; 476:6580.
Pemov A, Hansen NF, Sindiri S, et al. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1–associated atypical neurofibromas. Neuro-oncology 2019; 21:981992.